Ed Tate, Imperial College London

Everyone is welcome to the final talk in this term's ISMB Seminar Series from Professor Ed Tate, Imperial College London, Targeting Post-translational Modification for Drug Discovery.

The talk will be hosted by SMB PhD Student Representatives, Reuben Martin and Tracy (Yuhan) Zhao. 

Abstract: 

The Tate lab develops novel chemical biology approaches to enable drug discovery against post-translational modification (PTM) pathways and intractable drug targets, including chemical proteomic target identification, screening technologies, and chemical probe discovery for protein-protein interactions and enzymes modulating PTMs. Recent highlights include the first cell-active activity-based probes (ABPs) for deubiquitinases (DUBs), new tools for analysis and discovery of pathogenic secreted protease activities, and the first comprehensive maps of specific classes of PTMs through chemical proteomics. Our research in the field of protein lipidation led to several drug discovery and target validation campaigns, spanning antimalarial and antiviral research to oncology. We are also interested in new modalities including targeted protein degradation and antibody-drug conjugates (ADCs), and translation of technologies and drug candidates through biotech spinouts. These include Myricx Bio (https://myricxbio.com/), building on our discovery of ultrapotent (low/sub picomolar) protein lipidation inhibitors as a unique class of next generation payloads for antibody-drug conjugates (ADCs), and Siftr Bio (https://siftr.bio/), leveraging our platforms for ABP discovery and their application in patient-derived tissues.